Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $25,040.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now directly owns 13,000 shares in the company, valued at approximately $325,520. The trade was a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total value of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $28.56, for a total transaction of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $24,420.00.

Enliven Therapeutics Price Performance

ELVN opened at $24.15 on Friday. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -12.71 and a beta of 1.04. The company’s 50 day simple moving average is $24.66 and its two-hundred day simple moving average is $24.39. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03.

Analysts Set New Price Targets

Several research analysts recently weighed in on ELVN shares. Robert W. Baird upped their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Finally, BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $38.25.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC increased its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the last quarter. SG Americas Securities LLC purchased a new position in Enliven Therapeutics during the third quarter worth about $256,000. Verition Fund Management LLC acquired a new position in Enliven Therapeutics in the 3rd quarter valued at about $271,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.